{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:07Z","timestamp":1785402967790,"version":"3.56.0"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T00:00:00Z","timestamp":1459555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To determine the relationship of age to side\u2010effects leading to discontinuation of treatment in patients with stage Ta\u2013T1 non\u2010muscle\u2010invasive bladder cancer (\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      ) treated with maintenance bacille Calmette\u2013Gu\u00e9rin (\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated toxicity for 487 eligible patients with intermediate\u2010 or high\u2010risk Ta\u2013T1 (without carcinoma\n                      <jats:italic>in situ<\/jats:italic>\n                      )\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      randomised to receive 3 years of maintenance\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      therapy (247\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      alone and 240\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      + isoniazid) in European Organisation for Research and Treatment of Cancer Genito\u2010Urinary Group trial 30911. The percentage of patients who stopped for toxicity and the number of treatment cycles that they received were compared in four age groups, \u226460, 61\u201370, 71\u201375 and &gt;75 years, using the Mantel\u2013Haenszel chi\u2010square test for trend.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The percentage of patients stopping\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      for toxicity was 17.9% in patients aged \u226460 years, 21.9% in patients aged 61\u201370 years, 22.9% in patients aged 71\u201375 years, and 16.4% in patients aged &gt;75 years (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.90). For both systemic and local side\u2010effects, there was likewise no significant difference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In patients with intermediate\u2010 and high\u2010risk Ta\u2013T1\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      treated with\n                      <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                      , no differences in toxicity as a reason for stopping treatment were detected based on patient age.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13474","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T07:05:12Z","timestamp":1457247912000},"page":"423-428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non\u2010muscle\u2010invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette\u2013Gu\u00e9rin: results from European Organisation for Research and Treatment of Cancer Genito\u2010Urinary Group study 30911"],"prefix":"10.1111","volume":"118","author":[{"given":"Jorg R.","family":"Oddens","sequence":"first","affiliation":[{"name":"Department of Urology Jeroen Bosch Hospital \u2018s\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Department of Biostatistics European Organization for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio A.","family":"Brausi","sequence":"additional","affiliation":[{"name":"Department of Urology AUSL Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.","family":"Kirkels","sequence":"additional","affiliation":[{"name":"Department of Urology Erasmus MC Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van de Beek","sequence":"additional","affiliation":[{"name":"Department of Urology Maastricht UMC+ Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"van Andel","sequence":"additional","affiliation":[{"name":"Department of Urology OLVG Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[{"name":"Department of Urology Academic Medical Centre Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Prescott","sequence":"additional","affiliation":[{"name":"Department of Urology St James's University Hospital Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alfred Witjes","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud UMC Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Oosterlinck","sequence":"additional","affiliation":[{"name":"Department of Urology Gent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,2]]},"reference":[{"key":"e_1_2_7_2_1","article-title":"Guidelines on non\u2010muscle\u2010invasive bladder cancer (Ta, T1 and CIS)","author":"Babjuk M","year":"2015","journal-title":"Eur Urol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.05.033"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00371-3"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.04.005"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950101)75:1 <316::AID-CNCR2820751314>3.0.CO;2-T"},{"key":"e_1_2_7_8_1","first-page":"107","volume-title":"TNM Classification of Malignant Tumors","author":"UICC (International Union Against Cancer)","year":"1997"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.03.024"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66424-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.09.026"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.023"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)91755-3"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000156477"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65966-6"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:49:42Z","timestamp":1761742182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,2]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/bju.13474"],"URL":"https:\/\/doi.org\/10.1111\/bju.13474","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,2]]},"assertion":[{"value":"2016-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}